What is HC Wainwright’s Estimate for SPTX Q2 Earnings?

Seaport Therapeutics, Inc. (NASDAQ:SPTX) – Research analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for Seaport Therapeutics in a report issued on Wednesday, July 15th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($0.96) for the quarter. HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. HC Wainwright also issued estimates for Seaport Therapeutics’ Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.58) EPS, FY2026 earnings at ($3.25) EPS, Q1 2027 earnings at ($0.61) EPS, Q2 2027 earnings at ($0.64) EPS, Q3 2027 earnings at ($0.66) EPS, Q4 2027 earnings at ($0.69) EPS and FY2027 earnings at ($2.60) EPS.

Other equities research analysts also recently issued research reports about the company. Citigroup started coverage on Seaport Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $35.00 price target for the company. Leerink Partners initiated coverage on shares of Seaport Therapeutics in a report on Tuesday, May 26th. They issued an “outperform” rating and a $35.00 price objective on the stock. Zacks Research raised shares of Seaport Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Stifel Nicolaus assumed coverage on shares of Seaport Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $30.00 target price for the company. Finally, UBS Group downgraded shares of Seaport Therapeutics to a “sell” rating in a report on Tuesday, June 9th. Five investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $38.40.

Seaport Therapeutics Price Performance

Shares of NASDAQ SPTX opened at $20.85 on Monday. The company has a market cap of $1.12 billion and a P/E ratio of -2.02. Seaport Therapeutics has a 12 month low of $14.85 and a 12 month high of $23.00. The business’s 50 day simple moving average is $18.43.

Seaport Therapeutics (NASDAQ:SPTX) last released its quarterly earnings data on Monday, June 8th. The company reported ($10.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($10.64) by $0.30.

Insider Buying and Selling

In other news, major shareholder Arch Venture Partners Xii, Llc purchased 1,100,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was acquired at an average cost of $18.00 per share, with a total value of $19,800,000.00. Following the acquisition, the insider owned 6,294,951 shares in the company, valued at approximately $113,309,118. This trade represents a 21.17% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert J. Hombach purchased 13,000 shares of Seaport Therapeutics stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $18.14 per share, with a total value of $235,820.00. Following the completion of the purchase, the director directly owned 13,000 shares in the company, valued at $235,820. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Key Seaport Therapeutics News

Here are the key news stories impacting Seaport Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Seaport Therapeutics and assigned a $50 price objective, implying substantial upside from current levels.
• Neutral Sentiment: The firm issued detailed earnings estimates for upcoming quarters and fiscal years, including expected losses of ($0.96) in Q2 2026, ($0.54) in Q3 2026, ($0.58) in Q4 2026, and ($3.25) for FY2026. Article Title
• Neutral Sentiment: HC Wainwright also forecast continued losses in 2027, with EPS estimates of ($0.61) for Q1, ($0.64) for Q2, ($0.66) for Q3, ($0.69) for Q4, and ($2.60) for FY2027.